Development of Antipsychotic Medications with Novel Mechanisms of Action Based on Computational Modeling of Hippocampal Neuropathology

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Siekmeier, Peter J ^a,b   vanMaanen, David P ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; PHENYTOIN;

ARTICLE; CELL DENSITY; COMPUTER MODEL; CONTROLLED STUDY; DENDRITIC SPINE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SCREENING; GABAERGIC SYSTEM; GAMMA RHYTHM; HIPPOCAMPUS; NEUROPATHOLOGY; PROCESS MODEL; SCHIZOPHRENIA;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANTIPSYCHOTIC AGENTS; COMPUTER SIMULATION; DRUG DISCOVERY; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HUMANS; MODELS, NEUROLOGICAL; N-METHYLASPARTATE; NEURAL NETWORKS (COMPUTER); SCHIZOPHRENIA; USER-COMPUTER INTERFACE;

EID: 84875085552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058607     Document Type: Article

References (76)

1. Stilo SA, Murray RM, (2010) The epidemiology of schizophrenia: replacing dogma with knowlege. Dialogues in Clinical Neuroscience 12: 305-315.
2. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, et al. (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry 62: 19-28.
3. Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A, (2010) Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues in Clinical Neuroscience 12: 359382.
4. Heckers S, Konradi C, (2010) Hippocampal pathology in schizophrenia. Current Topics in Behavioral Neurosciences 4: 529-553.
5. Benes F, Berretta S, (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25: 1-27.
6. Coyle J, (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 4-6: 365-384.
7. Greene R, (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11: 569-577.
8. Hoffman RE, McGlashan TH (2003) Schizophrenia: From psychodynamic to neurodynamic theories. In: Sadock JS, Sadock VA, editors. Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins.
9. Feinberg I, (1982) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research 17: 319-334.
10. Beggs J, (2008) The criticality hypothesis: how local cortical networks might optimize information processing. Philosophical Transactions of the Royal Society A: Physical, Mathematical and Engineering Sciences 366: 329-343.
11. Lisman J, (2012) Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Current Opinion in Neurobiology 22: 537-544.
12. Cho RY, Konecky RO, Carter CS, (2006) Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proceedings of the National Academy of Sciences of the USA 103: 19878-19883.
13. Ferrarelli F, Massimini M, Peterson MJ, Riedner BA, Lazar M, et al. (2008) Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. American Journal of Psychiatry 165: 996-1005.
14. Hirano S, Hirano Y, Maekawa T, Obayashi C, Oribe N, et al. (2008) Abnormal neural oscillatory activity to speech sounds in schizophrenia: a magnetoencephalography study. Journal of Neuroscience 28: 4897-4903.
15. Spencer KM, Salisbury DF, Shenton ME, McCarley RW, (2008) Gamma-band auditory steady-state responses are imparied in first episode psychosis. Biological Psychiatry 64: 369-375.
16. Teale P, Collins D, Maharajh K, Rojas DC, Kronberg E, et al. (2008) Cortical source estimates of gamma band amplitude and phase are different in schizophrenia. Neuroimage 42: 1481-1489.
17. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, et al. (2006) Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biological Psychiatry 60: 1231-1240.
18. Kopell N, Ermentrout G, Whittington M, Traub R, (2000) Gamma rhythms and beta rhythms have different synchronization properties. Proceedings of the National Academy of Sciences of the USA 97: 1867-1872.
19. Wang X, (2006) Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia. Pharmacopsychiatry 39Suppl 1: S80-87.
20. Durstewitz D, Seamans J, (2008) The dual-state theory of prefrontal cortex dopamine function wiht relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biological Psychiatry 64: 739-749.
21. Hoffman RE, (1987) Computer simulations of neural information processing and the schizophrenia-mania dichotomy. Archives of General Psychiatry 44: 178-188.
22. Rolls ET, Loh M, Deco G, Winterer G, (2008) Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nature Reviews Neuroscience 9: 696-709.
23. Siekmeier PJ, Hasselmo ME, Howard MW, Coyle J, (2007) Modeling of context-dependent retrieval in hippocampal region CA1: Implications for cognitive function in schizophrenia. Schizophrenia Research 89: 177-190.
24. Traub RD, Jefferys JG, Miles R, Whittington MA, Toth K, (1994) A branching dendritic model of a rodent CA3 pyramidal neurone. Journal of Physiology (London) 481: 79-95.
25. Traub RD, Miles R, (1995) Pyramidal cell-to-inhibitory cell spike transduction explicable by active dendritic conductances in inhibitory cell. Journal of Computational Neuroscience 2: 291-298.
26. Siekmeier PJ, (2009) Evidence of multistability in a realistic computer simulation of hippocampus subfield CA1. Behavioural Brain Research 200: 220-231.
27. Tsai G, Passani L, Slusher B, Carter R, Baer L, et al. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry 52: 829-836.
28. Bergeron T, Coyle J, Tsai G, Greene R, (2005) NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30: 7-16.
29. Law A, Deakin J, (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neurochemistry 12: 2971-2974.
30. Harrison P, Law A, Eastwood S, (2003) Glutamate receptors and transporters in the hippocampus in schizophrenia. Annals of the New York Academy of Sciences 1003: 94-101.
31. Hoffman RE, Dobscha SK, (1989) Cortical pruning and the development of schizophrenia: a computer model. Schizophrenia Bulletin 15: 477-490.
32. Law A, Weickert C, Hyde T, Kleinman J, Harrison P, (2004) Reduced spinophilin but not microtubule-associated protein 2 express in the hippocampal formation in schizohprenia and mood disorders: Molecular evidence for a pathology of dendritic spines. American Journal of Psychiatry 161: 1848-1855.
33. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, et al. (1998) Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. Journal of Neurology, Neurosurgery, and Psychiatry 65: 446-453.
34. Devito L, Balu D, Kanter B, Lykken C, Basu A, et al. (2011) Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav 10: 210-222.
35. Heckers S, Stone D, Walsh J, Shick J, Koul P, et al. (2002) Differential Hippocampal Expression of Glutamic Acid Decarboxylase 65 and 67 Messenger RNA in Bipolar Disorder and Schizophrenia. Archives of General Psychiatry 59: 521-529.
36. Bird E, Barnes J, LL I, Spokes E, Mackay A, et al. (1977) Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. The Lancet 2: 1157-1158.
37. Fatemi S, Earle J, McMenomy T, (2000) Reduction in reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Molecular Psychiatry 5: 654-663.
38. Torrey E, Barci B, Webster M, Bartko J, Meador-Woodruff J, et al. (2005) Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychitry 57: 252-260.
39. Benes FM, Khan Y, Vincent SL, Wickramasinghe R, (1996) Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22: 338-349.
40. Lisman J, Coyle J, Green R, Javitt D, Benes F, et al. (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neuroscience 31: 234-242.
41. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, et al. (1999) Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Archives of General Psychiatry 56: 1001-1005.
42. Johansen TH, Chaudhary A, Verdoorn TA, (1995) Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol 48: 946-955.
43. Arai AC, Kessler M, Rogers G, Lynch G, (2000) Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol 58: 802-813.
44. Arai AC, Xia YF, Rogers G, Lynch G, Kessler M, (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 303: 1075-1085.
45. Atack JR, Wong DF, Fryer TD, Ryan C, Sanabria S, et al. (2010) Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,4-b]pyridazine (TPA023) in rats, primates, and humans. The Journal of Pharmacology and Experimental Therapeutics 332: 17-25.
46. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, et al. (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. American Journal of Psychiatry 165: 1585-1593.
47. Prenosil GA, Gasser EM, Rudolph U, Keist R, Fritschy J-M, et al. (2006) Specific subtypes of GABAA receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons. Journal of Neurophysiology 96: 846-857.
48. Kotaleski JH, Blackwell KT, (2010) Modeling the molecular mechanisms of synaptic plasticity using systems biology approaches. Nature Reviews Neuroscience 11: 239-251.
49. Lynch MA, (2004) Long-term potentiation and memory. Physiology Reviews 84: 87-136.
50. Cavazzini M, Bliss T, Emptage N, (2005) Ca2+ and synaptic plasticity. Cell Calcium 38: 355-367.
51. Shouval HZ, Bear MF, Cooper LN, (2002) A unified model of NMDA receptor-dependent bidirectional synaptic plasticity. Proc Natl Acad Sci U S A 99: 10831-10836.
52. Uhlhaas PJ, Singer W, (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11: 100-113.
53. Meyer-Lindenberg A, Weinberger D, (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Reviews Neuroscience 7: 818-827.
54. Vierling-Claassen D, Siekmeier P, Stufflebeam S, Kopell N, (2008) Modeling GABA alterations in schizophrenia: a link between impaired inhibition and altered gamma and beta range auditory entrainment. Journal of Neurophysiology 99: 2656-2671.
55. Kissler J, Muller MM, Fehr T, Rockstroh B, Elbert T, (2000) MEG gamma band activity in schizophrenia patients and healthy subjects in a mental arithmetic task and at rest. Clinical Neurophysiology 111: 2079-2087.
56. Beasley CL, Zhang ZJ, Patten I, Reynolds GP, (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry 52: 708-715.
57. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, et al. (2008) Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. American Journal of Psychiatry 165: 497-489.
58. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF, (2004) Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Molecular Psychiatry 9: 609-620.
59. Berk R, Bickel P, Campbell K, Fovell R, Keller-McNulty S, et al. (2007) Workshop on statistical approaches for the evaluation of complex computer models. Statistical Science 17: 173-192.
60. Bayarri M, Berger J, Cafeo G, Garcia-Donato F, Liu F, et al. (2007) Computer model validation with functional output. The Annals of Statistics 35: 1874-1906.
61. Easterling R, Berger J. Statistical foundations for the validation of computer models. In: Pace D, Stevenson S, editors; 2002. Society for Modeling and Simulation International.
62. Kilpatrick CJ, Wanwimolruk S, Wing LM, (1984) Plasma concentrations of unbound phenytoin in the management of epilepsy. British Journal of Clinical Pharmacology 17: 539-546.
63. Lampl I, Schwindt P, Crill W, (1998) Reduction of Cortical Pyramidal Neuron Excitability by the Action of Phenytoin on Persistent Na+ Current. Journal of Pharmacology and Experimental Therapeutics 284: 228-237.
64. Fink M, Irwin P, Sannita W, Papakostas Y, Green MA, (1979) Phenytoin: EEG effects and plasma levels in volunteers. Therapeutic Drug Monitoring 1: 93-103.
65. Chao TI, Alzheimer C, (1995) Effects of phenytoin on the persistent Na+ curent of mammalian CNS neurons. NeuroReport 6: 1778-1780.
66. Herkes GK, Lagerlund TD, Sharbrough FW, Eadie MJ, (1993) Effects of antiepileptic drug treatment on the background frequency of EEGs in epileptic patients. Journal of Clinical Neurophysiology 10: 210-216.
67. Van Wieringen A, Binnie CD, Meijer JWA, Peck AW, de Vries J, (1989) Comparison of the effects of lamotragine and phenytoin on the EEG power spectrum and cortical brainstem-evoked responses of normal human volunteers. Neuropsychobiology 21: 157-169.
68. Cunningham MO, Whittington MA, Bibbig A, Roopun AZ, LeBean REN, et al. (2004) A role for fast rhythmic bursting neurons in cortical gamma oscillations in vitro. Proceedings of the National Academy of Sciences of the United States of America 101: 7152-7157.
69. Deutz NEP, Chamuleau RA, Bovee WM, VanderWerf AJ, (1986) Effects of nimodipine on EEG and 31P-NMR spectra during and after incomplete forebrian ischemia in the rat. European Journal of Pharmacology 125: 429-435.
70. Denolle T, Sassano P, Allain H, Bentue-Ferrer D, Breton S, et al. (2002) Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundamental and Clinical Pharmacology 16: 527-535.
71. Sannita WG, Garbarino S, Gesino D, Massimilla S, Ogliastro C, (1999) Plasma concentrations and CNS effects of Ca antagonists darodpine and nimodipine after single-dose oral administration to healthy volunteers. Neuropsychobiolgy 40: 158-170.
72. Johansen TH, Chaudhary A, Verdoorn TA, (1995) Interactions among GYKI-52488, cyclothiazide, and anifacetam at recombinant AMPA and kainate receptors. Molecular Pharmacology 48: 946-955.
73. Arai AC, Kessler M, Rogers G, Lynch G, (2000) Effects of the potent amapkine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Molecular Pharmacology 58: 802-813.
74. Arai AC, Xia Y-F, Gogers G, Lynch G, Kessler M, (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. The Journal of Pharmacology and Experimental Therapeutics 303: 1075-1085.
75. Grove SJA, Jamieson C, Maclean JKF, Morrow JA, Rankovic Z, (2010) Positive allosteric modulators of the alpha-amino-3-hyroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. Journal of Medicinal Chemistry 53: 7271-7279.
76. Goff DC, Lamberti JS, Leaon AC, Green MF, Miller AL, et al. (2008) A placebo-controlled add-on trial of amapkine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33: 465-472.